SunWay Biotech Co., Ltd.

As of June 30, 2026, SunWay Biotech Co., Ltd. carries a market capitalization of 3.75B, placing it among publicly traded companies globally. Its enterprise value stands at 4.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SunWay Biotech Co., Ltd. has 60.09M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, SunWay Biotech Co., Ltd. maintains a current ratio of 1.49, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, SunWay Biotech Co., Ltd.'s stock has declined approximately 12.21% over the past 52 weeks. The 50-day moving average sits at 59.62, while the 200-day moving average is 59.83.

As of June 30, 2026, SunWay Biotech Co., Ltd. holds 726.41M in cash and equivalents against 1.65B in total debt, resulting in a net debt position of 684.24M. Total book value stands at 4.17B, with working capital of 740.41M providing operational flexibility.

SunWay Biotech Co., Ltd.'s most recent stock split took place on December 9, 2024 with a 297:302 split ratio.